AACR 2024 – Astra plays up PARP1 inhibition
Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.
AACR 2024 – BioNTech sees pancreatic promise amid neoantigen delays
When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.
AACR 2024 – Akeso impresses in stomach cancer
Fuelled with a $500m Summit windfall Akeso advances its lead bispecific.
AACR 2024 preview – Lag3, TIGIT and more
BeiGene has a strong presence at this year’s AACR, which features several notable duels.
AACR 2024 preview – “cancer vaccines” primed to underwhelm
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
AACR 2024 preview – clinical highlights and lowlights
The 2024 AACR abstract title drop features several noteworthy clinical studies.
GSK’s Blenrep Dreamm remains alive
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
